CagriSema Outperforms Semaglutide Alone on Key Obesity Body Targets
A post hoc analysis of REDEFINE 1 shows CagriSema drives more participants to healthy BMI and waist-to-height targets, improving cardiometabolic markers.
Summary
This analysis of the REDEFINE 1 trial examined whether CagriSema — a combination of cagrilintide and semaglutide — helped more people reach meaningful body composition targets compared to either drug alone or placebo. Researchers looked at how many participants achieved a BMI under 27 and a waist-to-height ratio under 0.53 after 68 weeks. About 30% of CagriSema users hit both targets, versus 19% on semaglutide, 9% on cagrilintide, and just 3% on placebo. Reaching these anthropometric targets was also strongly linked to improvements in blood sugar, blood pressure, triglycerides, and good cholesterol. Notably, absolute body measurements like BMI and waist-to-height ratio predicted cardiometabolic improvement at least as well — and at stricter thresholds, better than — percentage weight loss alone.
Detailed Summary
Obesity remains a central driver of metabolic aging, cardiovascular disease, and reduced healthspan. While percentage weight loss has long been the primary treatment benchmark, this analysis asks whether absolute anthropometric targets offer additional or superior predictive value for cardiometabolic health improvement.
Researchers performed a secondary, post hoc analysis of REDEFINE 1, a phase 3a, 68-week randomized controlled trial. Adults without diabetes and with a BMI of 30 or higher — or 27 or higher with at least one obesity-related complication — were assigned weekly injections of CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, all combined with lifestyle intervention. The analysis focused on the proportion of participants reaching BMI under 27 kg/m² and/or waist-to-height ratio under 0.53, and how achieving these targets correlated with cardiometabolic outcomes including normoglycemia, blood pressure under 130/80 mmHg, triglycerides, and HDL cholesterol.
CagriSema produced the most striking results: 30.3% of participants achieved both anthropometric targets at week 68, compared to 19.1% on semaglutide, 9.0% on cagrilintide, and 3.3% on placebo. Both BMI and waist-to-height ratio tracked similarly as indicators of cardiometabolic benefit. Critically, at more stringent cut-offs, these absolute measures outperformed percentage weight loss as predictors of clinical improvement.
These findings have significant implications for clinical practice. Using fixed body composition targets rather than relying solely on percentage weight loss may better capture who is achieving genuine cardiometabolic risk reduction. This supports a shift toward target-based obesity treatment strategies.
Caveats are important: this is a post hoc, secondary analysis, meaning it was not pre-specified and carries risk of multiple comparisons. The summary is based on the abstract only, so full methodological details and subgroup breakdowns are not available for review.
Key Findings
- 30.3% of CagriSema users hit both BMI <27 and waist-to-height ratio <0.53 targets, vs. 19.1% on semaglutide alone.
- Achieving anthropometric targets was linked to normalization of blood sugar, blood pressure, triglycerides, and HDL cholesterol.
- At stricter cut-off values, BMI and waist-to-height ratio outperformed percentage weight loss as cardiometabolic predictors.
- Cagrilintide alone achieved both targets in only 9% of participants, highlighting the combinational benefit of CagriSema.
- Results support using fixed body composition targets alongside percent weight loss in obesity treatment protocols.
Methodology
REDEFINE 1 was a phase 3a, 68-week randomized controlled trial in adults without diabetes with BMI ≥30 or ≥27 with complications. This was a secondary, post hoc analysis assessing anthropometric and cardiometabolic target attainment across four treatment arms. Post hoc design means findings are hypothesis-generating rather than confirmatory.
Study Limitations
This is a secondary, post hoc analysis of REDEFINE 1, not a pre-specified primary outcome assessment, which limits causal inference and increases risk of spurious findings. The summary is based on the abstract only, so full data tables, subgroup analyses, and adverse event profiles are unavailable. The trial enrolled adults without diabetes, limiting generalizability to people with type 2 diabetes or other metabolic comorbidities.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: